The Cancer Letter

Inside information on cancer research and drug development

Conversation with The Cancer Letter

As his center wins comprehensive (again), Carlos Arteaga tells us how NCI’s standards have evolved

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

NCI has renewed the Harold C. Simmons Comprehensive Cancer Center’s comprehensive designation.

“I think this is special, because I think it is a marker of an evolution of the institution, which has always been a basic science powerhouse, and now is enhancing an increasingly outstanding enterprise in translational cancer research and cancer care, community outreach and engagement, and education and training in cancer,” Carlos L. Arteaga, director of the Simmons Cancer Center at UT Southwestern, said to The Cancer Letter.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Byline
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusion
Minority Cancer Awareness Week

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more
By Kimlin Tam Ashing, Nadine J. Barrett, Kim F. Rhoads, Folakemi T. Odedina, Hayley S. Thompson and Camille C. R. Ragin
Byline
Paul Goldberg
Editor & Publisher
Table of Contents

Login

Looking for IP Login?